Compare Merck & Co., Inc. (MRK) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? Merck & Co., Inc. trades at $142.3 (market cap $352.29B), while Virgin Galactic Holdings, Inc. trades at $2.95 (market cap $456.30M). The key difference: Merck & Co., Inc. is far larger — about 772.1× Virgin Galactic Holdings, Inc.'s market cap, and Merck & Co., Inc. pays a 2.38% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| MRK | SPCE | |
|---|---|---|
Market Cap | $352.29B | $456.30M |
Volume | 6,348,796 | 4,518,834 |
Sector | Health | Industrials |
52-Week High | $156.43 | $7.52 |
52-Week Low | $82.49 | $2.17 |
Typical Hold Time | 98 Days | 69 Days |
Enterprise Value | $399.05B | $420.29M |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting persistent operational losses and a bearish technical outlook. The company continues to burn cash with negative gross and net profit margins, though recent earnings beats and strong ticket demand for future spaceflights offer a glimmer of hope. Cash flow trends show a gradual improvement, with a projected positive net cash flow of $25 million in 2026.
The outlook remains high-risk, high-reward. The path to profitability hinges on the successful commercial launch of Delta flights in 2027. While analyst sentiment is mixed and significant dilution and debt are concerns, the company's unique position in commercial spaceflight presents a speculative opportunity for investors with a long-term horizon and high risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
